EGFR and lung adenocarcinoma: Recent studies have shown that the SHH pathway is upregulated in a subset of lung adenocarcinoma with EGFR mutation [24,25], and inhibition of the SHH pathway can also enhance the activity of EGFR inhibitor gefitinib in pancreatic cancer cells [26].